Liraglutide

Nat Rev Drug Discov. 2010 Apr;9(4):267-8. doi: 10.1038/nrd3148.

Abstract

In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Approval
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / pharmacology
  • Glucagon-Like Peptide 1 / therapeutic use
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Liraglutide
  • Randomized Controlled Trials as Topic
  • United States
  • United States Food and Drug Administration

Substances

  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1